Immuneering Corp Cl A (IMRX)

$6.04 +0.41 (7.28%)
Market Cap 234.04M
Revenue (ttm) 0.00
Net Income (ttm) -61.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,080,000
Avg Vol 2,179,004
Day's Range N/A - N/A
Shares Out 41.57M
Stochastic %K 71%
Beta 0.47
Analysts Strong Sell
Price Target $16.60

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8080
Address:
245 Main Street, Second Floor, Cambridge, United States
BinaryLogic
BinaryLogic Oct. 25 at 12:54 PM
$IMRX [Stochastics] If you look at the 3YR Weekly chart, you will see that the SP pulled back inline with the 200DMA, RSI is back to a reasonable level, still with Bullish overall momentum. $6.0 is a consistent support/resistance line, and you can see that on the 1YR Daily. If/where the stock re-establishes this as support, look for a material upward continuation (IMO). Again-the Company just secured $200M in equity between Public/Private placement at $9.23. This fortifies the balance sheet, while continuing high-potential product pipeline. 50-100% upside, as I noted last week.
0 · Reply
AlbinoFace
AlbinoFace Oct. 24 at 6:40 PM
$IMRX
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 24 at 6:22 PM
$IMRX
0 · Reply
tgewaz1
tgewaz1 Oct. 24 at 4:39 PM
$IMRX Nice climb
0 · Reply
Gamer001
Gamer001 Oct. 24 at 4:38 PM
$IMRX $9 in horizon👏
0 · Reply
bioland
bioland Oct. 24 at 4:20 PM
$IMRX Finally...
0 · Reply
OptimistJP
OptimistJP Oct. 24 at 1:33 PM
$IMRX I can never really make sense of the market, so why would the underwriters exercise their option to purchase up to an additional 2,843,987 shares (as noted in the September 25, 2025, public offering announcement) at the offering price of $9.23 when they could easily purchase those shares on the open market as considerably less? No rush, right?
1 · Reply
BinaryLogic
BinaryLogic Oct. 24 at 11:19 AM
$IMRX The SP has retraced to the 100DMA following which time I estimate a consolidation period near term. MACD crossover, then move materially higher. 50-100% upside from this level (IMO) possible on broader positive market sentiment and continued strong test results. Recall-the latest Public/Private placement was completed at a $9.23 strike, securing the Company nearly $200M to support operations. The stock is now trading at/around $5.5-5.7.
0 · Reply
SpittingImage
SpittingImage Oct. 24 at 3:30 AM
$IMRX volume is slowing but thays a good thing for this stock.
0 · Reply
bioland
bioland Oct. 24 at 3:03 AM
$IMRX
0 · Reply
Latest News on IMRX
Immuneering Corporation - Special Call

Sep 29, 2025, 4:37 PM EDT - 25 days ago

Immuneering Corporation - Special Call

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 26, 2025, 4:01 PM EDT - 4 weeks ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Sep 25, 2025, 2:19 PM EDT - 4 weeks ago

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 25, 2025, 12:08 AM EDT - 4 weeks ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 4 weeks ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 24, 2025, 4:01 PM EDT - 4 weeks ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 16, 2025, 7:00 AM EDT - 5 weeks ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Sep 10, 2025, 7:00 AM EDT - 6 weeks ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Immuneering Announces Closing of $25 Million Private Placement

Aug 26, 2025, 4:05 PM EDT - 2 months ago

Immuneering Announces Closing of $25 Million Private Placement

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Aug 25, 2025, 8:00 AM EDT - 2 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Immuneering Announces $25 Million Private Placement

Aug 21, 2025, 8:00 AM EDT - 2 months ago

Immuneering Announces $25 Million Private Placement

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 4:05 PM EDT - 2 months ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 17, 2025, 6:00 AM EDT - 4 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 16, 2025, 8:00 AM EDT - 4 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 5 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025, 4:05 PM EDT - 6 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 7 months ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 7 months ago

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 4:05 PM EDT - 7 months ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 9 months ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Why Is Immuneering Stock Trading Higher On Tuesday?

Jan 7, 2025, 9:28 AM EST - 10 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 11 months ago

Immuneering Launches Pancreatic Cancer Advisory Board

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Dec 13, 2024, 2:10 PM EST - 11 months ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 12, 2024, 8:00 AM EST - 11 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 11 months ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19, 2024, 2:19 AM EDT - 1 year ago

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL ONCY

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 5:00 PM EST - 1 year ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Mar 4, 2024, 8:00 AM EST - 1 year ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Feb 20, 2024, 8:00 AM EST - 1 year ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Immuneering Announces Participation in February Investor Conferences

Feb 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Announces Participation in February Investor Conferences

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Dec 12, 2023, 8:00 AM EST - 2 years ago

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 4:05 PM EST - 2 years ago

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

BinaryLogic
BinaryLogic Oct. 25 at 12:54 PM
$IMRX [Stochastics] If you look at the 3YR Weekly chart, you will see that the SP pulled back inline with the 200DMA, RSI is back to a reasonable level, still with Bullish overall momentum. $6.0 is a consistent support/resistance line, and you can see that on the 1YR Daily. If/where the stock re-establishes this as support, look for a material upward continuation (IMO). Again-the Company just secured $200M in equity between Public/Private placement at $9.23. This fortifies the balance sheet, while continuing high-potential product pipeline. 50-100% upside, as I noted last week.
0 · Reply
AlbinoFace
AlbinoFace Oct. 24 at 6:40 PM
$IMRX
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 24 at 6:22 PM
$IMRX
0 · Reply
tgewaz1
tgewaz1 Oct. 24 at 4:39 PM
$IMRX Nice climb
0 · Reply
Gamer001
Gamer001 Oct. 24 at 4:38 PM
$IMRX $9 in horizon👏
0 · Reply
bioland
bioland Oct. 24 at 4:20 PM
$IMRX Finally...
0 · Reply
OptimistJP
OptimistJP Oct. 24 at 1:33 PM
$IMRX I can never really make sense of the market, so why would the underwriters exercise their option to purchase up to an additional 2,843,987 shares (as noted in the September 25, 2025, public offering announcement) at the offering price of $9.23 when they could easily purchase those shares on the open market as considerably less? No rush, right?
1 · Reply
BinaryLogic
BinaryLogic Oct. 24 at 11:19 AM
$IMRX The SP has retraced to the 100DMA following which time I estimate a consolidation period near term. MACD crossover, then move materially higher. 50-100% upside from this level (IMO) possible on broader positive market sentiment and continued strong test results. Recall-the latest Public/Private placement was completed at a $9.23 strike, securing the Company nearly $200M to support operations. The stock is now trading at/around $5.5-5.7.
0 · Reply
SpittingImage
SpittingImage Oct. 24 at 3:30 AM
$IMRX volume is slowing but thays a good thing for this stock.
0 · Reply
bioland
bioland Oct. 24 at 3:03 AM
$IMRX
0 · Reply
putsandcalls
putsandcalls Oct. 23 at 4:51 PM
$IMRX fwiw and im sure its nothing but nov call premiums ha ve moved up here.
1 · Reply
LabPsycho
LabPsycho Oct. 23 at 1:41 PM
$TNGX My guess is this is going to mirror the collapse 50% retrace of $IMRX after it went from ~ 1 to 10 then did an offering.
1 · Reply
CantNameThatTune
CantNameThatTune Oct. 23 at 9:38 AM
$IMRX Not enough poops floating around for it to matter. But the 9 mo results came late while the company organized the financing. That won't be the case this time. Company has met with FDA and these results will come sooner so you get dbl news of great 12 month survival followed immediately by an IND submitted and gladly accepted by The FDA.
0 · Reply
CantNameThatTune
CantNameThatTune Oct. 23 at 9:23 AM
$IMRX All u need to know as these one year survival ratesare coming at any time. If you were around earlier back ib Jul-Aug, which none of you were, the stock moved $1-$10 in advance of the 9 month results. https://www.biospace.com/drug-development/immuneering-asset-nearly-doubles-overall-survival-in-pancreatic-cancer-after-9-months
1 · Reply
Prosperity1_
Prosperity1_ Oct. 23 at 3:27 AM
$IMRX $RVMD
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 23 at 12:24 AM
$TNXP $IMRX $NUVB $CCCC $ALT five cheap biotechs worth holding long 💪
0 · Reply
bet_on_biotechs
bet_on_biotechs Oct. 22 at 11:55 PM
$IMRX The key question arises: Where is an investor likely to have a better chance of making money – with $RVMD or $IMRX? In the long term, there is absolutely no news about RVMD that could lead to a doubling of the SP. This is based on the lack of logic behind the scenario of simply multiplying an existing MCAP of $10 billion by $20 billion. Neither an assumed FDA approval nor initial product sales potentially received by RVMD will achieve this. From now on, the performance for speculators would no longer be satisfactory. Any significantly undervalued stock is likely to deliver better – and faster – performance. Let's compare IMRX – here, every positive news item likely brings with it the chance of topping RVMD's future annual performance. Simple theory – but one that will prove true.
0 · Reply
OptimistJP
OptimistJP Oct. 22 at 11:39 PM
$IMRX Watching $BYND today just made me think "what if". What if the Reddit group would target $IMRX? $BYND traded over 2 billion shares today and ran from $0.56 on Monday to over $7 today, including the trading of over 500 million shares even before the opening today. Imagine what the share price of $IMRX would be if we had a day with over 2 billion shares traded.
0 · Reply
bioland
bioland Oct. 22 at 4:35 PM
$IMRX Another 100K went short to keep it here...while they scoop it up with the other hand. Very obvious game here now...
1 · Reply
edward103
edward103 Oct. 22 at 2:31 PM
$IMRX I’m not adding to the FUD, I am only stating what should now be obvious. See for years they thought RAS could not be targeted. So IMRX went after MEK and it shows promise. But RVMD changed the game (for now). They showed you can indeed target RAS and successfully. As it’s prominent in PDAC (same space as IMRX) its starting to seem that IMRX is too late to the party i.e., RAS targeted therapy is the future NOT MEK. All the data is not in. But IF IMRX shows ~ 12mOS (great) that would still be least than RVMD in monotherapy. If someone was told they could take a pill and NO chemo what do you think they’ll opt for? So that is why IMRX us getting hit.
5 · Reply
SylvanEmperor
SylvanEmperor Oct. 22 at 2:24 PM
$IMRX yeah... Oversold now it seems.
0 · Reply
velle
velle Oct. 22 at 2:21 PM
$IMRX Ouch So much for the slow grind up above six
0 · Reply